Would you consider pembrolizumab treatment in metastatic gastric cancer with absence expression of a single mismatch repair enzyme?  

When PDL1 expression is negative, but IHC for mismatch repair expression is consistent with mismatch repair deficiency (MLH2, MSH2, and MSH6 expressed, PMS2 non-expressed), is pembrolizumab appropriate?